{"resourceType": "Composition", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"], "versionId": "2", "lastUpdated": "2025-12-08T13:42:49.209Z"}, "contained": [{"resourceType": "EvidenceVariable", "id": "NCT03421379-AllCauseMortality", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "All-cause mortality (timeframe for NCT03421379)", "status": "active", "definition": {"concept": {"text": "All-cause mortality"}}, "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-SeriousAdverseEvents", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Serious Adverse Events (timeframe for NCT03421379)", "status": "active", "definition": {"concept": {"text": "Serious Adverse Events"}}, "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvents", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Other Adverse Events (timeframe for NCT03421379)", "status": "active", "definition": {"concept": {"text": "Other Adverse Events"}}, "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-AllCauseMortality-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_AllCauseMortality_EG000", "title": "All-cause mortality for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-AllCauseMortality", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberAffected": 0, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-SeriousAdverseEvents-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_SeriousAdverseEvents_EG000", "title": "Serious Adverse Events for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-SeriousAdverseEvents", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberAffected": 0, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvents-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvents_EG000", "title": "Other Adverse Events for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvents", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.2112676056338028}, "numberAffected": 15, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-AllCauseMortality-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_AllCauseMortality_EG001", "title": "All-cause mortality for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-AllCauseMortality", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberAffected": 0, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "Evidence", "id": "NCT03421379-SeriousAdverseEvents-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_SeriousAdverseEvents_EG001", "title": "Serious Adverse Events for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-SeriousAdverseEvents", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014285714285714285}, "numberAffected": 1, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvents-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvents_EG001", "title": "Other Adverse Events for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvents", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.18571428571428572}, "numberAffected": 13, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "Evidence", "id": "NCT03421379-SeriousAdverseEvent-0-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_SeriousAdverseEvent_0_EG000", "title": "Vertigo positional as serious adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-SeriousAdverseEvent-0", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-SeriousAdverseEvent-0-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_SeriousAdverseEvent_0_EG001", "title": "Vertigo positional as serious adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-SeriousAdverseEvent-0", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014285714285714285}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-SeriousAdverseEvent-0", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Vertigo positional as serious adverse event", "status": "active", "definition": {"concept": {"text": "Vertigo positional as serious adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Serious Adverse Event"}, {"text": "Ear and labyrinth disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-0-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_0_EG000", "title": "Ear pain as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-0", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.028169014084507043}, "numberOfEvents": 2, "numberAffected": 2, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-0-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_0_EG001", "title": "Ear pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-0", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-0", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Ear pain as other adverse event", "status": "active", "definition": {"concept": {"text": "Ear pain as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Ear and labyrinth disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-1-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_1_EG000", "title": "Eye pain as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-1", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014084507042253521}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-1-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_1_EG001", "title": "Eye pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-1", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-1", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Eye pain as other adverse event", "status": "active", "definition": {"concept": {"text": "Eye pain as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Eye disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-2-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_2_EG000", "title": "Eye pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-2", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014084507042253521}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-2-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_2_EG001", "title": "Eye pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-2", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-2", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Eye pruritus as other adverse event", "status": "active", "definition": {"concept": {"text": "Eye pruritus as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Eye disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-3-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_3_EG000", "title": "Lacrimation increased as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-3", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014084507042253521}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-3-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_3_EG001", "title": "Lacrimation increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-3", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-3", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Lacrimation increased as other adverse event", "status": "active", "definition": {"concept": {"text": "Lacrimation increased as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Eye disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-4-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_4_EG000", "title": "Diarrhoea as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-4", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014084507042253521}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-4-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_4_EG001", "title": "Diarrhoea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-4", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-4", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Diarrhoea as other adverse event", "status": "active", "definition": {"concept": {"text": "Diarrhoea as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Gastrointestinal disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-5-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_5_EG000", "title": "Nausea as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-5", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.07042253521126761}, "numberOfEvents": 5, "numberAffected": 5, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-5-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_5_EG001", "title": "Nausea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-5", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.15714285714285714}, "numberOfEvents": 11, "numberAffected": 11, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-5", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Nausea as other adverse event", "status": "active", "definition": {"concept": {"text": "Nausea as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Gastrointestinal disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-6-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_6_EG000", "title": "Toothache as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-6", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014084507042253521}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-6-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_6_EG001", "title": "Toothache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-6", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014285714285714285}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-6", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Toothache as other adverse event", "status": "active", "definition": {"concept": {"text": "Toothache as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Gastrointestinal disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-7-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_7_EG000", "title": "Vomiting as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-7", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.028169014084507043}, "numberOfEvents": 2, "numberAffected": 2, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-7-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_7_EG001", "title": "Vomiting as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-7", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.05714285714285714}, "numberOfEvents": 5, "numberAffected": 4, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-7", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Vomiting as other adverse event", "status": "active", "definition": {"concept": {"text": "Vomiting as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Gastrointestinal disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-8-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_8_EG000", "title": "Feeling abnormal as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-8", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-8-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_8_EG001", "title": "Feeling abnormal as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-8", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014285714285714285}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-8", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Feeling abnormal as other adverse event", "status": "active", "definition": {"concept": {"text": "Feeling abnormal as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "General disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-9-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_9_EG000", "title": "Cystitis as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-9", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-9-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_9_EG001", "title": "Cystitis as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-9", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014285714285714285}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-9", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Cystitis as other adverse event", "status": "active", "definition": {"concept": {"text": "Cystitis as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Infections and infestations"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-10-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_10_EG000", "title": "Blood pressure decreased as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-10", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014084507042253521}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-10-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_10_EG001", "title": "Blood pressure decreased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-10", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.02857142857142857}, "numberOfEvents": 2, "numberAffected": 2, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-10", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Blood pressure decreased as other adverse event", "status": "active", "definition": {"concept": {"text": "Blood pressure decreased as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Investigations"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-11-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_11_EG000", "title": "Blood pressure increased as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-11", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.056338028169014086}, "numberOfEvents": 4, "numberAffected": 4, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-11-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_11_EG001", "title": "Blood pressure increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-11", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-11", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Blood pressure increased as other adverse event", "status": "active", "definition": {"concept": {"text": "Blood pressure increased as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Investigations"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-12-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_12_EG000", "title": "Back pain as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-12", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014084507042253521}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-12-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_12_EG001", "title": "Back pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-12", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-12", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Back pain as other adverse event", "status": "active", "definition": {"concept": {"text": "Back pain as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Musculoskeletal and connective tissue disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-13-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_13_EG000", "title": "Headache as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-13", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014084507042253521}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-13-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_13_EG001", "title": "Headache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-13", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014285714285714285}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-13", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Headache as other adverse event", "status": "active", "definition": {"concept": {"text": "Headache as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Nervous system disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-14-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_14_EG000", "title": "Nasal congestion as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-14", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014084507042253521}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-14-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_14_EG001", "title": "Nasal congestion as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-14", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-14", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Nasal congestion as other adverse event", "status": "active", "definition": {"concept": {"text": "Nasal congestion as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Respiratory, thoracic and mediastinal disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-15-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_15_EG000", "title": "Nasal pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-15", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014084507042253521}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-15-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_15_EG001", "title": "Nasal pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-15", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-15", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Nasal pruritus as other adverse event", "status": "active", "definition": {"concept": {"text": "Nasal pruritus as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Respiratory, thoracic and mediastinal disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-16-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_16_EG000", "title": "Oropharyngeal pain as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-16", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014084507042253521}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-16-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_16_EG001", "title": "Oropharyngeal pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-16", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-16", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Oropharyngeal pain as other adverse event", "status": "active", "definition": {"concept": {"text": "Oropharyngeal pain as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Respiratory, thoracic and mediastinal disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-17-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_17_EG000", "title": "Rhinalgia as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-17", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.08450704225352113}, "numberOfEvents": 6, "numberAffected": 6, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-17-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_17_EG001", "title": "Rhinalgia as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-17", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-17", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Rhinalgia as other adverse event", "status": "active", "definition": {"concept": {"text": "Rhinalgia as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Respiratory, thoracic and mediastinal disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-18-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_18_EG000", "title": "Cold sweat as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-18", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-18-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_18_EG001", "title": "Cold sweat as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-18", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014285714285714285}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-18", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Cold sweat as other adverse event", "status": "active", "definition": {"concept": {"text": "Cold sweat as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Skin and subcutaneous tissue disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-19-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_19_EG000", "title": "Hot flush as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-19", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-19-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_19_EG001", "title": "Hot flush as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-19", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014285714285714285}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-19", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Hot flush as other adverse event", "status": "active", "definition": {"concept": {"text": "Hot flush as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Vascular disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-20-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_20_EG000", "title": "Hypertension as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-20", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-20-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_20_EG001", "title": "Hypertension as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-20", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014285714285714285}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-20", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Hypertension as other adverse event", "status": "active", "definition": {"concept": {"text": "Hypertension as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Vascular disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-21-EG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_21_EG000", "title": "Peripheral coldness as other adverse event for Glucagon Nasal Powder in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Nasal Powder", "variableRole": "population", "observed": {"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-21", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0}, "numberOfEvents": 0, "numberAffected": 0, "sampleSize": {"knownDataCount": 71}}]}, {"resourceType": "Evidence", "id": "NCT03421379-OtherAdverseEvent-21-EG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"]}, "name": "NCT03421379_OtherAdverseEvent_21_EG001", "title": "Peripheral coldness as other adverse event for Glucagon Hydrochloride Solution in NCT03421379", "status": "active", "variableDefinition": [{"description": "Glucagon Hydrochloride Solution", "variableRole": "population", "observed": {"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"}}, {"note": [{"text": "All randomized participants who received at least one dose of study drug."}], "variableRole": "outcome", "observed": {"reference": "#NCT03421379-OtherAdverseEvent-21", "type": "EvidenceVariable"}}], "statistic": [{"statisticType": {"text": "Percentage"}, "quantity": {"value": 0.014285714285714285}, "numberOfEvents": 1, "numberAffected": 1, "sampleSize": {"knownDataCount": 70}}]}, {"resourceType": "EvidenceVariable", "id": "NCT03421379-OtherAdverseEvent-21", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "title": "Peripheral coldness as other adverse event", "status": "active", "definition": {"concept": {"text": "Peripheral coldness as other adverse event"}}, "definitionModifier": [{"code": {"text": "Adverse event assessment type"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/definition-method", "code": "systematic-assessment", "display": "Systematic Assessment"}]}}, {"code": {"text": "Source Vocabulary for Adverse Event Definition"}, "valueCodeableConcept": {"text": "MedDRA 18.1"}}], "classifier": [{"text": "Other Adverse Event"}, {"text": "Vascular disorders"}], "timing": {"text": "From Baseline to End of Follow-up (Up to 2 Months)"}, "handling": "boolean"}], "identifier": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}], "text": "FEvIR Object Identifier"}, "system": "https://fevir.net/FOI", "value": "399874", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-adverse-events-report", "assigner": {"display": "Computable Publishing LLC"}}], "status": "final", "type": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "OutcomeMeasureReport", "display": "OutcomeMeasureReport"}], "text": "Outcome Measure Report"}, "author": [{"display": "[No author listed.]"}], "title": "Adverse Events Report for NCT03421379", "id": "399874", "url": "https://fevir.net/resources/Composition/399874", "date": "2025-12-08T13:42:49.209Z", "custodian": {"reference": "Organization/118079", "type": "Organization", "display": "Computable Publishing LLC"}, "relatesTo": [{"type": "cite-as", "targetMarkdown": "Adverse Events Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399874. Revised 2025-12-08. Available at: https://fevir.net/resources/Composition/399874. Computable resource at: https://fevir.net/resources/Composition/399874#json."}], "section": [{"title": "Events Frequency Threshold", "code": {"text": "EventsFrequencyThreshold"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">0%</div>"}}, {"title": "Events Time Frame", "code": {"text": "EventsTimeFrame"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">From Baseline to End of Follow-up (Up to 2 Months)</div>"}}, {"title": "Events Description", "code": {"text": "EventsDescription"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug.</div>"}}, {"title": "Glucagon Nasal Powder", "code": {"text": "EG000 Glucagon Nasal Powder"}, "section": [{"title": "Event Group Description", "code": {"text": "EventGroupDescription"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"}}]}, {"title": "Glucagon Hydrochloride Solution", "code": {"text": "EG001 Glucagon Hydrochloride Solution"}, "section": [{"title": "Event Group Description", "code": {"text": "EventGroupDescription"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"}}]}, {"title": "Total Mortality", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Total Mortality"}, "focus": {"reference": "#NCT03421379-AllCauseMortality", "type": "EvidenceVariable", "display": "All-cause mortality (timeframe for NCT03421379)"}, "entry": [{"reference": "#NCT03421379-AllCauseMortality-EG000", "type": "Evidence", "display": "All-cause mortality for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-AllCauseMortality-EG001", "type": "Evidence", "display": "All-cause mortality for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Total Serious Events", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Total Serious Events"}, "focus": {"reference": "#NCT03421379-SeriousAdverseEvents", "type": "EvidenceVariable", "display": "Serious Adverse Events (timeframe for NCT03421379)"}, "entry": [{"reference": "#NCT03421379-SeriousAdverseEvents-EG000", "type": "Evidence", "display": "Serious Adverse Events for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-SeriousAdverseEvents-EG001", "type": "Evidence", "display": "Serious Adverse Events for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Total Other Events", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Total Other Events"}, "focus": {"reference": "#NCT03421379-OtherAdverseEvents", "type": "EvidenceVariable", "display": "Other Adverse Events (timeframe for NCT03421379)"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvents-EG000", "type": "Evidence", "display": "Other Adverse Events for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvents-EG001", "type": "Evidence", "display": "Other Adverse Events for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Serious Event List", "code": {"text": "SeriousEventList"}, "section": [{"title": "Vertigo positional", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-SeriousAdverseEvent-0", "type": "EvidenceVariable", "display": "Vertigo positional as serious adverse event"}, "entry": [{"reference": "#NCT03421379-SeriousAdverseEvent-0-EG000", "type": "Evidence", "display": "Vertigo positional as serious adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-SeriousAdverseEvent-0-EG001", "type": "Evidence", "display": "Vertigo positional as serious adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}]}, {"title": "Other Event List", "code": {"text": "OtherEventList"}, "section": [{"title": "Ear pain", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-0", "type": "EvidenceVariable", "display": "Ear pain as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-0-EG000", "type": "Evidence", "display": "Ear pain as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-0-EG001", "type": "Evidence", "display": "Ear pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Eye pain", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-1", "type": "EvidenceVariable", "display": "Eye pain as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-1-EG000", "type": "Evidence", "display": "Eye pain as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-1-EG001", "type": "Evidence", "display": "Eye pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Eye pruritus", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-2", "type": "EvidenceVariable", "display": "Eye pruritus as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-2-EG000", "type": "Evidence", "display": "Eye pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-2-EG001", "type": "Evidence", "display": "Eye pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Lacrimation increased", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-3", "type": "EvidenceVariable", "display": "Lacrimation increased as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-3-EG000", "type": "Evidence", "display": "Lacrimation increased as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-3-EG001", "type": "Evidence", "display": "Lacrimation increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Diarrhoea", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-4", "type": "EvidenceVariable", "display": "Diarrhoea as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-4-EG000", "type": "Evidence", "display": "Diarrhoea as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-4-EG001", "type": "Evidence", "display": "Diarrhoea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Nausea", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-5", "type": "EvidenceVariable", "display": "Nausea as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-5-EG000", "type": "Evidence", "display": "Nausea as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-5-EG001", "type": "Evidence", "display": "Nausea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Toothache", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-6", "type": "EvidenceVariable", "display": "Toothache as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-6-EG000", "type": "Evidence", "display": "Toothache as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-6-EG001", "type": "Evidence", "display": "Toothache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Vomiting", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-7", "type": "EvidenceVariable", "display": "Vomiting as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-7-EG000", "type": "Evidence", "display": "Vomiting as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-7-EG001", "type": "Evidence", "display": "Vomiting as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Feeling abnormal", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-8", "type": "EvidenceVariable", "display": "Feeling abnormal as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-8-EG000", "type": "Evidence", "display": "Feeling abnormal as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-8-EG001", "type": "Evidence", "display": "Feeling abnormal as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Cystitis", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-9", "type": "EvidenceVariable", "display": "Cystitis as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-9-EG000", "type": "Evidence", "display": "Cystitis as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-9-EG001", "type": "Evidence", "display": "Cystitis as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Blood pressure decreased", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-10", "type": "EvidenceVariable", "display": "Blood pressure decreased as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-10-EG000", "type": "Evidence", "display": "Blood pressure decreased as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-10-EG001", "type": "Evidence", "display": "Blood pressure decreased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Blood pressure increased", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-11", "type": "EvidenceVariable", "display": "Blood pressure increased as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-11-EG000", "type": "Evidence", "display": "Blood pressure increased as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-11-EG001", "type": "Evidence", "display": "Blood pressure increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Back pain", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-12", "type": "EvidenceVariable", "display": "Back pain as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-12-EG000", "type": "Evidence", "display": "Back pain as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-12-EG001", "type": "Evidence", "display": "Back pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Headache", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-13", "type": "EvidenceVariable", "display": "Headache as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-13-EG000", "type": "Evidence", "display": "Headache as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-13-EG001", "type": "Evidence", "display": "Headache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Nasal congestion", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-14", "type": "EvidenceVariable", "display": "Nasal congestion as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-14-EG000", "type": "Evidence", "display": "Nasal congestion as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-14-EG001", "type": "Evidence", "display": "Nasal congestion as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Nasal pruritus", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-15", "type": "EvidenceVariable", "display": "Nasal pruritus as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-15-EG000", "type": "Evidence", "display": "Nasal pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-15-EG001", "type": "Evidence", "display": "Nasal pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Oropharyngeal pain", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-16", "type": "EvidenceVariable", "display": "Oropharyngeal pain as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-16-EG000", "type": "Evidence", "display": "Oropharyngeal pain as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-16-EG001", "type": "Evidence", "display": "Oropharyngeal pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Rhinalgia", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-17", "type": "EvidenceVariable", "display": "Rhinalgia as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-17-EG000", "type": "Evidence", "display": "Rhinalgia as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-17-EG001", "type": "Evidence", "display": "Rhinalgia as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Cold sweat", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-18", "type": "EvidenceVariable", "display": "Cold sweat as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-18-EG000", "type": "Evidence", "display": "Cold sweat as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-18-EG001", "type": "Evidence", "display": "Cold sweat as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Hot flush", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-19", "type": "EvidenceVariable", "display": "Hot flush as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-19-EG000", "type": "Evidence", "display": "Hot flush as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-19-EG001", "type": "Evidence", "display": "Hot flush as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Hypertension", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-20", "type": "EvidenceVariable", "display": "Hypertension as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-20-EG000", "type": "Evidence", "display": "Hypertension as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-20-EG001", "type": "Evidence", "display": "Hypertension as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}, {"title": "Peripheral coldness", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}]}, "focus": {"reference": "#NCT03421379-OtherAdverseEvent-21", "type": "EvidenceVariable", "display": "Peripheral coldness as other adverse event"}, "entry": [{"reference": "#NCT03421379-OtherAdverseEvent-21-EG000", "type": "Evidence", "display": "Peripheral coldness as other adverse event for Glucagon Nasal Powder in NCT03421379"}, {"reference": "#NCT03421379-OtherAdverseEvent-21-EG001", "type": "Evidence", "display": "Peripheral coldness as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"}]}]}]}